 |
12 Diseases |  |
0 Trials |
|
0 Trials |  |
5 News |  |
- | Tivicay (dolutegravir) / GSK, ViiV Healthcare, Vitekta (elvitegravir) / Japan Tobacco, Gilead
Clinical, Review, Journal: Structure Based Drug Design: Clinically relevant HIV1 Integrase Inhibitors. (Pubmed Central) - Apr 9, 2019
Into the bargain, Raltegravir, Elvitegravir and Dolutegravir have been approved by FDA as anti-HIV agents...Additionally, the structural features required for overcoming HIV resistance have been discussed. These insights will update the ongoing design of novel antiviral inhibitors.
- BMS707035 / BMS
Trial withdrawal: A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected Subjects (clinicaltrials.gov) - Apr 25, 2012
P2, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
These insights will update the ongoing design of novel antiviral inhibitors. Terminated --> Withdrawn
- BMS707035 / BMS
Enrollment change: A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected Subjects (clinicaltrials.gov) - Apr 25, 2012
P2, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
Terminated --> Withdrawn N=50 --> 0